Pre-Made Tagraxofusp biosimilar, Protein drug conjugate: Recombinant therapeutic protein drug conjugate for drug discovery and mechanism of action (MOA) research

Recombinant therapeutic protein drug conjugate (Pre-made Tagraxofusp biosimilar, Protein drug conjugate) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).[3][4] It was approved for use in the United States in 218,[5] and after a second review, in the EU in January 221.[2] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6] Tagraxofusp is an engineered molecule composed of Diptheria toxin covalently attached to a portion of the interleukin-3 cytokine. The drug binds to the ¦Â-chain of the interleukin-3 receptor (CD123), which mediates endocytosis.51 The Diptheria toxin is subsequently released and induces cytotoxicity through protein inhibition.